ReviewBoneKEy reports2015
Cancer-associated muscle weakness: What's bone got to do with it?
Review in BoneKEy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.Cancer metastasis reviews · 2026Review
- Human neuromuscular organoids mimic cancer-induced muscle cachexia.Cell reports methods · 2026Article
- Review
- Acute RyR1 CaNature communications · 2021Article
- Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.Biochimica et biophysica acta. Reviews on cancer · 2020Review
- Cancer- and Chemotherapy-Induced Musculoskeletal Degradation.JBMR plus · 2019Review
- Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice.Frontiers in endocrinology · 2019Article
- Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.Muscle & nerve · 2018Article
- ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.Scientific reports · 2017Article
- Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.Journal of bone oncology · 2017Review
- Reactive Oxygen Species/Nitric Oxide Mediated Inter-Organ Communication in Skeletal Muscle Wasting Diseases.Antioxidants & redox signaling · 2017Review
- Bone Pain and Muscle Weakness in Cancer Patients.Current osteoporosis reports · 2017Review
- Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis.Current osteoporosis reports · 2017Review
- State of the art in anti-cancer mAbs.Journal of biomedical science · 2017Review
- Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.Frontiers in endocrinology · 2017Article
- Minocycline attenuates cardiac dysfunction in tumor-burdened mice.Journal of molecular and cellular cardiology · 2016Article
- An analysis of the relationship between metastases and cachexia in lung cancer patients.Cancer medicine · 2016Article
- In Vitro Co-Culture Models of Breast Cancer Metastatic Progression towards Bone.International journal of molecular sciences · 2016Review
- Article
- Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study.Clinical Medicine Insights. Oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer-associated muscle weakness is an important paraneoplastic syndrome for which there is currently no treatment. Tumor cells commonly metastasize to bone in advanced cancer to disrupt normal bone remodeling and result in morbidity that includes muscle weakness. Tumor in bone stimulates excessive osteoclast activity, which causes the release of growth factors stored in the mineralized bone matrix. These factors fuel a feed-forward vicious cycle of tumor growth in bone and bone destruction. Recent evidence indicates that these bone-derived growth factors can act systemically to cause muscle weakness. Muscle weakness can be caused by reduced muscle mass or reduced muscle function; in advanced disease, it is likely due to a combination of both reduced quantity and quality of muscle. In this review, we discuss possible mechanisms that lead to skeletal muscle weakness due to bone metastases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.